7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 
      
    		                                           
      cash flows from operating activities
    		                                           
      net income
    		-90,787,000 -65,561,000 -45,629,000 -35,417,000 -24,940,000 -22,250,000 -27,356,000 -24,605,000 -22,534,000 -19,225,000 -19,531,000 -19,559,000 -15,773,000 -17,432,000 -16,103,000 -12,356,000 -13,243,000 -15,381,000 -14,010,000 -10,948,000 -9,288,000 -9,572,000 -9,687,000 -7,450,000 -5,731,000 -7,674,000 -4,924,000 -5,240,000 -6,600,000 -6,672,000 -3,551,000 -4,084,473 -6,099,658 -5,171,634 -5,221,900 -3,644,609 -3,807,432 -3,692,793 -3,586,988 -5,090,963 -4,736,544 -7,865,066 -5,711,415 
      adjustments to reconcile net income to net cash from operating activities
    		                                           
      amortization of investment premiums
    		-2,029,000 -2,391,000 -3,133,000 -4,031,000 -4,979,000 -5,436,000 -2,821,000 -2,702,000 -3,145,000 -1,966,000 -389,000 -53,000 143,000 457,000 670,000 755,000 972,000       454,000    -71,000 -5,000 87,000 62,000 15,962 29,401 18,637 30,645 36,773 31,951 36,536 48,475 64,207 63,562   
      amortization of financing costs
    		8,000 24,000 24,000 24,000 24,000 18,000 28,000 26,000 2,000 32,000 28,000 8,000 27,000 12,000 12,000 12,000 -35,000 20,000 21,000 21,000 20,000 20,000 45,000 46,000 40,000 30,000 30,000 30,000 30,000 30,000 30,000 33,516 17,568 421,781 98,179 92,849        
      stock-based compensation
    		7,336,000 13,547,000 11,348,000 5,667,000 8,982,000 7,082,000 7,981,000 4,080,000 4,481,000 4,620,000 3,569,000 2,156,000 1,940,000 2,220,000 2,357,000 1,433,000 1,599,000 1,491,000 1,577,000 1,042,000 1,475,000 1,649,000 1,652,000 976,000 811,000 922,000 1,034,000 617,000 750,000 631,000 610,000 363,840 344,128 341,258 402,239 358,575 320,953 490,245 624,554 527,444 601,592 1,471,509 903 
      amortization of right-of-use assets
    		114,000 112,000 111,000 110,000 87,000 75,000 74,000 74,000 73,000 73,000 72,000 72,000 142,000 0 77,000 76,000 75,000 73,000 72,000 71,000 70,000 68,000 68,000                     
      realized (gain) loss on investment
    		-10,000                                           
      interest expense related to operating lease liability
    		8,000 8,000 10,000 11,000 9,000 9,000 9,000 10,000 10,000 11,000 12,000 12,000 25,000 0 4,000 0 2,000 4,000 5,000 7,000 7,000 8,000 10,000                     
      changes in operating assets and liabilities:
    		                                           
      prepaid expenses and other current assets
    		-4,834,000 -5,089,000 -9,554,000 1,505,000 -2,728,000 -79,000 1,748,000 -58,000 1,373,000 7,351,000 -2,258,000 -1,432,000 823,000 -2,544,000 23,000 -307,000 1,254,000 -1,392,000 -266,000 112,000 -1,176,000 632,000 569,000 -6,670,000 -175,000 -610,000 75,000 1,686,000 -427,000 -1,080,000 -316,000 198,264 245,535 -167,483 221,310 181,200 108,227 -203,802 187,704 424,255 -912,432 -576,031 -15,564 
      accrued interest, net of interest receivable on maturity of investments
    		2,204,000 -11,000 2,470,000 -646,000 1,347,000 -157,000 655,000 -101,000 246,000                                   
      accounts payable
    		-1,081,000 -2,209,000 -2,110,000 9,561,000 -10,835,000 5,864,000 -2,287,000 1,801,000 100,000 1,813,000 -4,732,000 5,387,000 -2,963,000 2,954,000 1,707,000 -1,390,000 -1,377,000 -637,000 860,000 1,230,000 -452,000 127,000 650,000 343,000 219,000 194,000 716,000 -175,000 -330,000 829,000 -832,000 31,385 174,971 -465,782 522,935 376,825 -102,088 -47,253 449,701 81,951 92,849 7,131 37,306 
      accrued expenses
    		-4,802,000 14,643,000 -5,739,000 -7,836,000 11,280,000 -13,551,000 15,923,000 3,922,000 -177,000 -3,989,000 -1,572,000           -356,000 1,840,000 519,000 1,283,000 710,000 -118,000 337,000 1,015,000 544,000 -428,000 -477,484 318,488 696,814 472,143 281,704 252,381 77,300 -752,680 315,584 1,052,508 129,280 62,707 
      lease liability
    		-130,000 -130,000 -129,000 -128,000 -96,000 -90,000 -88,000 -87,000 -87,000 -88,000 -85,000 -84,000 -112,000 83,000 -76,000 -86,000 -85,000 -86,000 -85,000 -85,000 -83,000 -82,000 -83,000                     
      net cash from operating activities
    		-94,003,000 -47,061,000 -52,331,000 -31,181,000 -21,962,000 -28,513,000 -6,134,000 -17,640,000 -19,658,000 -11,435,000 -24,643,000 -10,926,000 -13,499,000 -13,442,000 -10,530,000 -12,350,000 -10,926,000 -13,434,000 -10,876,000 -5,486,000 -5,323,000 -6,666,000 -4,302,000 -11,743,000 -3,398,000 -6,459,000 -3,152,000 -2,679,000 -5,503,000 -5,270,000 -5,303,000 -3,948,002 -3,328,003 -4,203,170 -3,278,592 -2,464,884 -2,654,415 -3,226,840 -2,725,124 -3,299,390 -3,400,454 -1,620,709 -410,941 
      cash flows from investing activities
    		                                           
      purchases of investments
    		-21,454,000 -123,476,000 -232,614,000 -136,960,000 -149,985,000 -229,822,000 -596,601,000 -97,533,000 -79,399,000 -243,976,000 -57,395,000 -44,606,000 -10,445,000 -35,698,000 -30,682,000 -35,570,000 -24,167,000 -59,602,000 -48,676,000 -32,963,000 -108,682,000 -82,556,000 -56,435,000 -80,048,000 -99,474,000 -83,666,000 -99,218,000 -180,914,000 -53,583,000 -81,428,000 -32,279,000 -9,419,476 -2,680,171 -4,368,643 -6,057,417 -4,658,784 -2,016,972 -10,097,119 -149,360 0 -3,858,975   
      proceeds from sales and maturities of investments
    		       133,266,000 66,865,000 39,493,000 59,593,000                       3,604,000 8,096,000 6,106,000 2,458,000 5,266,000 6,122,000 1,956,000    
      net cash from investing activities
    		160,025,000 42,506,000 63,245,000 6,584,000 25,901,000 -126,059,000 -459,792,000 35,733,000 -12,534,000 -204,483,000 2,198,000 7,260,000 26,894,000 18,980,000 1,619,000 27,410,000 13,617,000 3,560,000 -6,627,000 30,269,000 -9,634,000 9,780,000 11,152,000 -11,061,000 15,154,000 10,979,000 -7,609,000 -142,391,000 -27,086,000 -66,625,000 -29,627,000 -4,395,476 1,391,829 -764,643 2,038,583 1,447,216 441,028 -4,831,119 5,972,640 1,956,000 -3,251,975   
      cash flows from financing activities
    		                                           
      public offering, net of offering costs
    		   0 0 -25,000 597,119,000 0 -73,000                                   
      value of shares withheld related to employee tax withholding
    		   0 0 0 -42,101,000 0 0 -5,407,000 -1,714,000 -1,034,000 0 0 -499,000 0 -234,000 0 -473,000 0 -169,000 0 -127,000 -27,000 -2,000 -38,000 -84,000 -26,000 -2,000   -7,628 -213   -5,210 -2,092   0 0   
      proceeds from exercises of stock options and other stock issuances
    		480,000 507,000 349,000                                         
      atm offering, net of fees
    		   0 0 0 46,658,000 0 0 0 1,969,000                                 
      net cash from financing activities
    		480,000 507,000 349,000 1,000,000 2,522,000 2,905,000 606,037,000 188,000 -74,000 267,078,000 4,184,000 10,749,000 10,000 -1,590,000 -5,006,000 47,000 -256,000 1,898,000 5,191,000 464,000 37,000 416,000 33,000 229,000 73,000 260,000 325,000 343,000 167,485,000 70,149,000 62,298,000 14,763,893 1,110,586 4,002,418 2,523,553 1,038,278 108,349 9,259,126 -57,303 -28,175 -704,656 22,964,969 -17,909 
      net increase in cash and cash equivalents
    		66,502,000 -4,048,000 11,263,000 -23,597,000 6,461,000 -151,667,000 140,111,000 18,281,000 -32,266,000   7,083,000    15,107,000 2,435,000 -7,976,000 -12,312,000 25,247,000 -14,920,000 3,530,000 6,883,000 -22,575,000 11,829,000 4,780,000 -10,436,000 -144,727,000 134,896,000 -1,746,000 27,368,000 6,420,415 -825,588 -965,395 1,283,544 20,610 -2,105,038 1,201,167 3,190,213 -1,371,565 -7,357,085   
      cash and cash equivalents beginning of period
    		0 0 26,676,000 0 0 0 55,516,000 0 0 0 36,632,000 0 0 0 26,371,000 0 0 0 29,117,000 0 0 0 8,377,000 0 0 0 24,779,000 0 0 0 8,988,000 0 0 0 3,075,502 0 0 0 768,550 0    
      effect of exchange rate changes on cash
    		-6,000 -12,000 1,000 -74,000 -29,000 3,000 -48,000 50,000 -68,000 -3,000 -9,000 141,000 -223,000                               
      cash and cash equivalents end of period
    		66,496,000 -4,060,000 37,940,000 -23,671,000 6,432,000 -151,664,000 195,579,000 18,331,000 -32,334,000 51,157,000 18,362,000 7,224,000 13,182,000 3,772,000 12,454,000 15,107,000 2,435,000 -7,976,000 16,805,000 25,247,000 -14,920,000 3,530,000 15,260,000 -22,575,000 11,829,000 4,780,000 14,343,000 -144,727,000 134,896,000 -1,746,000 36,356,000 6,420,415 -825,588 -965,395 4,359,046 20,610 -2,105,038 1,201,167 3,958,763 -1,371,565    
      supplemental disclosure of non-cash investing and financing transactions
    		                                           
      unpaid deferred public offering and other financing costs
    		0 0 50,000 0 -25,000 6,000 69,000 0 16,000 -18,000 52,000 6,000 -25,000 0 50,000 -19,000 19,000 0 50,000 0 0 -16,000 66,000 -8,000     -26,000 173,000 136,000 -79,924 71,705 131,749 16,055         
      right-of-use asset obtained in exchange for lease obligation
    		   0        0 0 0 1,664,000                             
      proceeds from maturities of investments
    		 165,982,000 295,859,000  175,886,000 103,763,000 136,809,000      37,339,000 54,678,000 32,301,000  37,784,000 63,162,000 42,049,000  99,048,000 92,336,000 67,587,000  114,628,000 94,645,000 91,609,000  26,497,000 14,803,000 2,652,000             
      realized gain on investment
    		   -1,000 -113,000                                       
      repurchase of common stock
    		           0 0 -1,674,000 -5,121,000                             
      proceeds from warrant and option exercises and stock issuances under employee stock purchase plan
    		       188,000 -1,000 2,615,000 3,966,000 150,000 0 84,000 614,000  5,000 1,898,000 5,664,000  206,000 442,000 160,000                     
      proceeds from option exercises and employee stock purchase plan common stock issuance
    		    2,522,000                                       
      proceeds from option exercises
    		      4,361,000                                     
      realized loss on investment
    		            0                               
      accrued interest, net of interest received on maturity of investments
    		          243,000 115,000 151,000 243,000 105,000 594,000 -11,000 759,000 -166,000 673,000                        
      public offering and financing costs
    		          -37,000     -19,000    0 0   -7,000    -283,000 -216,000 -120,000 -146,000 -376,272 -61,940 -46,055 -15,990 -71,624        
      net decrease in cash and cash equivalents
    		          -18,261,000   3,948,000 -13,917,000                             
      amortization of non-cash clinical trial costs
    		                       0 0 6,000 134,000 125,000 64,000 252,000 225,000 345,464 248,894 357,259 42,328         
      realized gain on investments
    		                   -26,000                        
      other accrued liabilities
    		            2,098,000 523,000 694,000  -77,000 674,000 -22,000                         
      public offering and finance costs
    		                                           
      receivable from exercise of warrants
    		                  173,000                         
      proceeds from stock issuance under employee stock purchase plan and warrant exercises
    		                                           
      amortization of investment premiums (accretion of investment discounts)
    		                  1,138,000  1,078,000 853,000 636,000   -37,000 -101,000                 
      realized (gain) loss on investments
    		                     -13,000 -2,000                     
      amortization of debt discount on notes payable
    		                           0 0 146,000 258,000 258,152 256,596 336,656 431,227 431,227 431,227 524,977 400,657 240,516 240,515   
      change in fair value of debt conversion feature liability
    		                           0 0 -37,000 -1,361,000 -632,628 1,136,074 -570,676 -277,698 -620,087 64,514 -412,050 -96,547 216,841 197,496 546,485 82,656 
      proceeds from issuances of common stock, net of underwriting discounts and commissions
    		                           0 165,205,000 72,580,000 58,822,000 14,519,612 1,250,000 4,042,735 2,539,543 1,103,996 525,772       
      repayment of convertible notes payable
    		                           0 0   0    0 0       
      supplemental disclosure of cash flow information:
    		                                           
      cash paid during the period for interest
    		                           0 0   0    0 0       
      realized loss on investments
    		                         0 2,000                 
      proceeds from warrant and option exercises and stock issuance under employee stock purchase plan
    		                         298,000 409,000  2,498,000               
      deposits
    		                                           
      shares issued to cover future clinical trial costs
    		                               0 0 0 1,800,000         
      shares issued as commitment fee in connection with lincoln park agreement
    		                               0            
      proceeds from warrant and option exercises
    		                              3,622,000             
      repurchases of common stock
    		                                       0    
      shares issued as commitment fee in connection with aspire agreement
    		                                   0        
      shares issued in lieu of loan payment to related party
    		                                   0 0       
      proceeds from stock issuance under employee stock purchase plan
    		                                0   11,345 0   20,489 0   
      change in fair value of accrued license fees
    		                                       0 0 4,421,337 4,960,511 
      shares issued in lieu of license fee payment
    		                                           
      conversion of notes payable
    		                                       0 0   
      issuance of common stock to consultant
    		                                       0 57,520   
      shares issued in lieu of license fee payment to related party
    		                                           
      public offering costs
    		                                     -551,947 -57,303 -48,664 -704,656   
      unpaid deferred public offering costs
    		                                     -27,423 409,414     
      accounts payable - related party
    		                                           
      accrued license fees
    		                                           
      proceeds from convertible notes payable
    		                                           
      issuance of common stock in exchange for notes receivable
    		                                           
      net proceeds from issuances of common stock
    		                                        0   
      shares issued in lieu of license fee
    		                                        58,495,422   
      unpaid deferred ipo costs
    		                                           
      cash, and cash equivalents beginning of period
    		                                           
      cash, and cash equivalents end of period
    		                                           
      amortization of discount charged to interest expense on convertible notes
    		                                          171,955 
      deferred ipo financing costs paid
    		                                          -17,909 
      net increase in cash
    		                                          -428,850 
      cash, beginning of period
    		                                          755,857 
      cash, end of period
    		                                          327,007 
      deferred ipo costs included in accounts payable and accrued expenses
    		                                          2,057,903 
      •
    		                                           
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.